Лечение артериальной гипертензии в особых группах больных. Гипертрофия левого желудочка
Аннотация
Об авторе
А. О. КонрадиРоссия
Список литературы
1. European Society of Hypertension- European Society of Cardiology guidelines for the management оf arterial hypertension. J Hypertension 2003; 21: 1011-53. 2. JNC
2. Sokolow M., Pertoff D. Prognosis of essential hypertension treated conservatively. Circulation 1961; 23: 697- 713.
3. Vakili B.A., Oken P.M., Devereux R.B. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334-41.
4. Kannel W., Gordon T., Devereux R.B. Left ventricular hypertrophy by electrocardiogram: prevalence, incidence, and mortality in the Framingham Study. Ann Intern Med 1969: 71: 89-105.
5. Levy D. Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study. Drugs 1988: 56 (Suppl. 5): 1-5.
6. Liao Y., Cooper R., Mensah G. et al. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995: 273: 1592-7.
7. Schillaci G., Verdecchia P., Porcellati С. et al. Continuous relation between left ventricular mass and risk in essential hypertension. Hypertension 2000: 35: 580-6.
8. Casale P.N., Devereux R.B., Miner M. et al. Value of echocardiographic measurements of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986: 105: 173-8.
9. Ghali J., Kadakia S., Cooper R. et al. Impact of left ventricular hypertrophy patterns on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 1991; 17: 1277-82.
10. Kohara K., Zhao B., Jiang Y. et al. Relation of left ventricular hypertrophy and geometry to asymptomatic cerebrovascular damage in essential hypertension. Am J Cardiol 1999: 83 (3): 367-70.
11. Levy D., Anderson K.M., Savage D.D. et al. Risk of ventricular arrhythmias in left ventricular hypertrophy: The Framingham Heart Study. Am J Cardiol 285-92.
12. Messerly F.N., Grodzicki T. Hypertensive left ventricular hypertrophy, ventricular arrhythmias and sudden death. Eur Heart J 1992: 13 (Suppl. D): 66-9.
13. James M., Jones J. Ventricular arrhythmia in untreated newly presenting hypertensive patients compared with matched control population. J Hypertens 1989: 7: 409-15.
14. Nunez B.D., Lavie C.J. Comparison of diastolic left ventricular filling and cardiac dysrhythmias in hypertensive patients with and without isolated septal hypertrophy. Am J Cardiol 1994; 74: 585-90.
15. Kannel W.B. Left ventricular hypertrophy as a risk factor. J Hypertens 1991: 9 (Suppl. 2): S3-S9.
16. Canau A., Devereux R.B., Roman M.J. et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension, J Am Coll Cardiol 1992: 19: 1550-8.
17. Koren M.J., Devereux R.B., Casale P.N. el al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension Ann Intent Med 1991: 114: 345-52.
18. Krumbolz H.M., Larson M., Levy D. Prognosis of left ventricular geometric patterns in Framingham Heart Study. J Am Coll Cardiol 1995; 25: 884-97.
19. Jennings C., Wong J., Regression of Left ventricular hypertrophy in hypertension: Changing patterns with successive meta-analysis. J Hypertens Suppl 1998; 16: S29-S34.
20. Devereux R.B., Dahlof B. Requirements for an informative trial on left ventricular hypertrophy regression. J Hum Hypertension 1994; 8: 735-9.
21. Dahlof B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients - A metaanalysis if 109 treatment studies. Am J Hypertens 1992: 5: 95-110.
22. Cruickshank J.M., Lewes J., Moore E.V., Dodd С. Reversibility of left ventricular hypertrophy by different types of antihypertensive therapy. J Hum Hypertens 1992; 17: 85-90.
23. Schmeider R.E., Schilachi M.P., Klingheil A., Martus P. Update of Reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996) Nephrol Dial Transplant 1998: 13: 564-9.
24. Klingbeil A.U., Schneider M., Martus P. A meta-analysis o/the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003 Jul: 115 (1):41-6.
25. Cuspidi С., Muiesan M.L., Valagussa L. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002: 20 (11): 2293-300.
26. Dahlof B., Devereux R.B., Kjelddsen S.E. et al. Cardiovascular morbidity and mortality in the It ЕЕ study: a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
27. Koren M.J., Savage D.D., Casale P.N. et al. Changes in left ventricular mass predict risk in essential hypertension. Circulation 1990; 82:11129.
28. Yurenev A.P. et al. Management of essential hypertension inpatients with different degrees of Left ventricular hypertrophy: Multicentral trial. Am J Hypertens 1992; 5: 182s-9s.
29. Levy D., Salomon M., D'Agonistino R. et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994: 90: 1786-93.
30. Mathew J., Sleight P., Lonn E. et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin enzyme inhibitor, ramipril. Circulation 2001: 104: 1615-21.
31. Muiesan M.L., Salvetti M., Rizzoni D. et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13: 1091-7.
32. Verdecchia P., Schillaci C., Borgioni I. et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998. 97: 48-55.
Рецензия
Для цитирования:
Конради А.О. Лечение артериальной гипертензии в особых группах больных. Гипертрофия левого желудочка. Артериальная гипертензия. 2005;11(2):105-110.